Fig. 5: RPL22L1 enhances TMZ resistance and can be reversed by Stattic.

A–F GBM cells were treated with TMZ (7.5 μmol/L), Gefitinib (10 μmol/L), Stattic (5 μmol/L), TMZ+Gefitinib, TMZ+Stattic for 48 h, DMSO was the negative control. A, B MTS experiment and CCK8 assay were performed to detect proliferation of T98G-RPL22L1/T98G-Vec cells (A) and LN229-RPL22L1/LN229-Vec cells (B). C, D T98G-RPL22L1/T98G-Vec cells (C) and LN229-RPL22L1/LN229-Vec cells (D) were treated at the specified concentration for 48 h and IC50 were determined by MTS and CCK8 methods. E, F Colony formation tests of T98G-RPL22L1/T98G-Vec cells (E) and LN229-RPL22L1/LN229-Vec cells (F). All data were shown as mean ± SD of three independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001, Student’s t test). G–I LN229-RPL22L1/LN229-Vec cells were injected subcutaneously into the right shoulder of nude mice. One week later, intraperitoneal injection of TMZ (60 mg/kg), TMZ+Stattic (5 mg/kg) to nude mice bearing tumors for 13 days. After drug treatment, the subcutaneous tumors were taken, photographed (G) and weighed (I). The tumor size (H) was monitored every other day and statistics were performed (n = 4, *P < 0.05, Student’s t test).